SYNTHESIS & EVAL OF 1,5,6 TRIAZACHRYSENE & 5,6,11 TRIAZACHRYSENE DERIVATIVES

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 我们的主要研究兴趣是新药的发现和开发。几年来，我们的研究小组一直致力于设计和合成新型非喜树碱拓扑异构酶I靶向的抗肿瘤药物。已经确定了几种有效的拓扑异构酶I靶向试剂。研究正在进行中，以确定这些化合物中更有希望发展到临床的候选药物。最近，我们实验室的研究已经开始开发选择性结合和稳定G-四链DNA的试剂。我们目前正在探索这些G-四链稳定剂在癌症化疗中的前景和全部潜力。此外，我们的研究小组已经开始研究发现新的先导化合物，用于开发同工酶特异的拓扑异构酶II靶向药物，用于未来开发这类癌症化疗药物中改进的临床药物。 欲了解更多信息，请访问http://medchem.rutgers.edu/lavoie.shtml

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Our primary research interests are in the discovery and the development of novel pharmaceuticals. For several years our research group has focused on the design and synthesis of novel non-camptothecin topoisomerase I-targeting antitumor agents. Several potent topoisomerase I-targeting agents have been identified. Studies are in progress to identify among these compounds the more promising candidates for development into the clinic. Recently, studies in our laboratory have been undertaken to develop agents that will selectively bind and stabilize G-quadruplex DNA. We are presently exploring the promise and full potential of these G-quadruplex stabilizers in cancer chemotherapy. In addition, our research group has initiated research into the discovery of new lead compounds for the development of isozyme specific topoisomerase II-targeting agents for the future development of an improved clinical agent within this class of cancer chemotherapeutic agents. See more at http://medchem.rutgers.edu/lavoie.shtml